KPIs & Operating Metrics(New)
Growth Metrics

Teva Pharmaceutical Industries (TEVA) Debt Ratio (2016 - 2026)

Teva Pharmaceutical Industries (TEVA) has disclosed Debt Ratio for 18 consecutive years, with 0.42 as the latest value for Q1 2026.

  • Quarterly Debt Ratio fell 4.2% to 0.42 in Q1 2026 from the year-ago period, while the trailing twelve-month figure was 0.42 through Mar 2026, down 4.2% year-over-year, with the annual reading at 0.41 for FY2025, 8.79% down from the prior year.
  • Debt Ratio for Q1 2026 was 0.42 at Teva Pharmaceutical Industries, up from 0.41 in the prior quarter.
  • The five-year high for Debt Ratio was 0.49 in Q1 2022, with the low at 0.41 in Q4 2025.
  • Average Debt Ratio over 5 years is 0.46, with a median of 0.46 recorded in 2023.
  • The sharpest move saw Debt Ratio decreased 0.21% in 2023, then fell 8.79% in 2025.
  • Teva Pharmaceutical Industries' Debt Ratio stood at 0.48 in 2022, then decreased by 5.36% to 0.46 in 2023, then decreased by 0.87% to 0.45 in 2024, then fell by 8.79% to 0.41 in 2025, then grew by 0.68% to 0.42 in 2026.
  • Per Business Quant, the three most recent readings for TEVA's Debt Ratio are 0.42 (Q1 2026), 0.41 (Q4 2025), and 0.42 (Q3 2025).